As previously stated, breast cancer‐targeted PLGA nanoparticles containing siRNA targeting NGF suppress NGF‐mediated proliferation of sympathetic nerves post‐chemotherapy, thereby demonstrating enhanced anticancer efficiency [100]. This evidence concerns the gene NGF and breast carcinoma.